Uso de la octreótida en ascitis refractaria después de un trasplante hepático
- Oana Anisa Nutu 1
- Alejandro Manrique Municio 1
- Alberto A. Marcacuzco Quinto 1
- Jorge Calvo Pulido 1
- Luis Carlos Jiménez Romero 1
- 1 Hospital Universitario 12 de Octubre. Madrid
ISSN: 2340-416, 1130-0108
Año de publicación: 2019
Volumen: 111
Número: 11
Páginas: 882-884
Tipo: Artículo
Otras publicaciones en: Revista Española de Enfermedades Digestivas
Objetivos de desarrollo sostenible
Resumen
Refractory ascites is a condition associated with a reduced survival and a poorer quality of life. Portal hyperflow after liver transplantation is one of the main causes. We report the case of a female patient with refractory ascites after liver transplantation who was treated with splenic embolization. Ascites persisted despite embolization due to splenic revascularization by short gastric vessels and repeat embolization was technically unfeasible. Based on pathophysiology data, she was treated with octreotide, a somatostatin octapeptide analog, which resulted in splanchnic vasoconstriction and a reduction of the portal flow and venous pressure. After four months of treatment with octreotide, the patient had a good clinical status without ascites.